Practical Guidelines on Implementing Hypofractionated Radiotherapy for Prostate Cancer in Africa.
Africa
guidelines
hypofractionation
prostate cancer
radiotherapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
06
2021
accepted:
15
11
2021
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Among a growing body of literature in global oncology, several articles project increased cost savings and radiotherapy access by adopting hypofractionated radiotherapy (HFRT) in low- and middle-income countries (LMICs) like those in Africa. Clinical trials in Europe and the USA have demonstrated HFRT to be non-inferior to conventional radiotherapy for eligible patients with several cancers, including prostate cancer. This could be a highly recommended option to battle a severely large and growing cancer burden in resource-limited regions. However, a level of implementation research may be needed in limited resource-settings like in Africa. In this article, we present a list of evidence-based recommendations to practice HFRT on eligible prostate cancer patients. As literature on HFRT is still developing, these guidelines were compiled from review of several clinical trials and professionally accredited material with minimal resource requirements in mind. HFRT guidelines presented here include patient eligibility, prescription dose schedules, treatment planning and delivery techniques, and quality assurance procedures. The article provides recommendations for both moderately hypofractionated (2.4-3.4Gy per fraction) and ultrahypofractionated (5Gy or more per fraction) radiation therapy when administered by 3D-Conformal Radiotherapy, Intensity Modulated Radiation Therapy, or Image-Guided Radiotherapy. In each case radiation oncology health professionals must make the ultimate judgment to ensure safety as more LMIC centers adopt HFRT to combat the growing scourge of cancer.
Identifiants
pubmed: 34926247
doi: 10.3389/fonc.2021.725103
pmc: PMC8673781
doi:
Types de publication
Journal Article
Langues
eng
Pagination
725103Informations de copyright
Copyright © 2021 Swanson, Samba, Lavelle, Elzawawy, Sajo, Ngwa and Incrocci.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The Reviewer NL declared a past co-authorship with several of the authors WS, RS, AE, ES, WN, and LI to the handling editor.
Références
JCO Glob Oncol. 2020 Apr;6:667-678
pubmed: 32343628
Radiother Oncol. 2017 Nov;125(2):178-185
pubmed: 28947098
Med Phys. 2006 Oct;33(10):3874-900
pubmed: 17089851
Med Phys. 2016 Jul;43(7):4209
pubmed: 27370140
Med Phys. 2012 Apr;39(4):1946-63
pubmed: 22482616
Med Phys. 2001 May;28(5):712-37
pubmed: 11393467
Front Oncol. 2021 Feb 19;10:618641
pubmed: 33680940
Med Phys. 2009 Sep;36(9):4197-212
pubmed: 19810494
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
Lancet Oncol. 2021 Feb;22(2):235-245
pubmed: 33444529
J Clin Oncol. 2018 Oct 11;:JCO1801097
pubmed: 30307776
Med Phys. 2011 Mar;38(3):1313-38
pubmed: 21520843
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Med Phys. 1994 Apr;21(4):581-618
pubmed: 8058027
Lancet Oncol. 2016 Aug;17(8):1061-1069
pubmed: 27339116